Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma
- 19 March 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 479, 31-41
- https://doi.org/10.1016/j.canlet.2020.03.016
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81802299, 81502514)
- CAMS Innovation Fund for Medical Sciences (2016-I2M-1-001, 2017-I2M-1-005)
- Fundamental Research Funds for the Central Universities (3332018070)
- National Key Basic Research Development Plan (2018YFC1312105)
This publication has 47 references indexed in Scilit:
- Challenges to effective cancer control in China, India, and RussiaThe Lancet Oncology, 2014
- Thoc1 inhibits cell growth via induction of cell cycle arrest and apoptosis in lung cancer cellsMolecular Medicine Reports, 2014
- Lung cancer: potential targets for immunotherapyThe Lancet. Respiratory Medicine, 2013
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant CancersClinical Cancer Research, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradicationImmunological Reviews, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient CohortsJournal of Clinical Oncology, 2006
- Intracellular serpin SERPINB6 (PI6) is abundantly expressed by human mast cells and forms complexes with β-tryptase monomersBlood, 2004